Jonathan Zhang
@jzhangecon.bsky.social
Assistant Professor, Duke Sanford
www.jonathanzhang.net
www.jonathanzhang.net
Reposted by Jonathan Zhang
Examining GLP-1s usage using data on 1.4M diabetic or obese veterans finds that PCP adoption drives large metabolic improvements matching trials—but no short-run cuts to emergency department use or medical spending, from Bock, Moshfegh, and @jzhangecon.bsky.social www.nber.org/papers/w34667
January 15, 2026 at 4:01 PM
Examining GLP-1s usage using data on 1.4M diabetic or obese veterans finds that PCP adoption drives large metabolic improvements matching trials—but no short-run cuts to emergency department use or medical spending, from Bock, Moshfegh, and @jzhangecon.bsky.social www.nber.org/papers/w34667
Reposted by Jonathan Zhang
Two new preprints on the efx of GLP-1s just dropped.
They use different samples, data, & designs.
But they come to the same conclusion on one point:
GLP-1s do not generate meaningful short- to medium-run reductions in non-GLP-1 medical spending, despite clear health benefits.
They use different samples, data, & designs.
But they come to the same conclusion on one point:
GLP-1s do not generate meaningful short- to medium-run reductions in non-GLP-1 medical spending, despite clear health benefits.
January 12, 2026 at 3:06 PM
Two new preprints on the efx of GLP-1s just dropped.
They use different samples, data, & designs.
But they come to the same conclusion on one point:
GLP-1s do not generate meaningful short- to medium-run reductions in non-GLP-1 medical spending, despite clear health benefits.
They use different samples, data, & designs.
But they come to the same conclusion on one point:
GLP-1s do not generate meaningful short- to medium-run reductions in non-GLP-1 medical spending, despite clear health benefits.
🚨Do GLP-1s “pay for themselves”? We study real-world impacts at scale. An estimated 1 in 8 Americans have tried GLP-1s. But beyond clinical trials, we know surprisingly little about their real-world effects.
Paper: nber.org/papers/w34667 (w/
@jasminmoshfegh.bsky.social
& Sam Bock)
🧵1/10
Paper: nber.org/papers/w34667 (w/
@jasminmoshfegh.bsky.social
& Sam Bock)
🧵1/10
Weighing the Impacts of GLP-1s: Quasi-Experimental Evidence From Provider Adoption
Founded in 1920, the NBER is a private, non-profit, non-partisan organization dedicated to conducting economic research and to disseminating research findings among academics, public policy makers, an...
nber.org
January 12, 2026 at 1:47 PM
🚨Do GLP-1s “pay for themselves”? We study real-world impacts at scale. An estimated 1 in 8 Americans have tried GLP-1s. But beyond clinical trials, we know surprisingly little about their real-world effects.
Paper: nber.org/papers/w34667 (w/
@jasminmoshfegh.bsky.social
& Sam Bock)
🧵1/10
Paper: nber.org/papers/w34667 (w/
@jasminmoshfegh.bsky.social
& Sam Bock)
🧵1/10
We examine how bias in a widely used medical device against individuals with darker skin tones propagates into disparities in subsequent medical treatment
Black patients systematically receive lower rates of follow-up care than white patients even when the screening results would suggest they should receive higher rates of care, from @marcellaalsan.bsky.social, Liran Einav, Amy Finkelstein, and Jonathan Zhang https://www.nber.org/papers/w34168
August 29, 2025 at 6:31 PM
We examine how bias in a widely used medical device against individuals with darker skin tones propagates into disparities in subsequent medical treatment